SLC5A2 and type 1 diabetes mellitus: While CGM parameters have been explored in a 2-week T1DM trial of the SGLT2 inhibitor dapagliflozin, in which highest doses showed a trend toward improved glucose variability compared to placebo,[15] the current analysis represents a longer-term study specifically evaluating diurnal patterns in the effect of these agents.